Journal Logo

Manufacturers News

Manufacturers News

Author Information
doi: 10.1097/01.HJ.0000725108.92778.01
  • Free

UNITRON INTRODUCES REMOTE ADJUST TECHNOLOGY

Unitron has introduced an app that features remote fine-tuning and adjustment capability for their hearing aids.

Hearing care professionals can send adjustments directly to an app on the patient's smartphone. Giving patients control of when hearing aids are optimized empowers them to manage their hearing care outside of clinic hours or protocols. Providing remote adjustments also allows patients who live in remote regions, face accessibility or health issues, and experience scheduling conflicts to access care when it's most convenient for them.

“Businesses are rapidly adapting in response to customer needs, and we know hearing care should be part of that too,” said Shaun Coghlan, Senior Product Manager of eSolutions at Unitron. “With remote adjust, we're making it possible to receive the high level of care they're used to without the worry of trying to get into the clinic.”

Remote adjust offers a solution for audiology patients considering safety measures during the COVID-19 pandemic. It also helps patients bypass longer than usual wait times when updating the gain or compression of their hearing aid. Also, this technology allows patients to decide what is right for them and how much control they want to take with their hearing aid settings, ensuring they can be active participants in their hearing care.

BLUEPRINT SOLUTIONS NOW FEATURES IDA TELECARE

Blueprint Solutions has integrated Ida Institute's Telecare patient survey tools into its office management system (OMS). Ida Telecare offers people with hearing loss easy-to-use tools and resources to help them prepare for audiology appointments and successfully manage daily communication. These online survey form tools can now be issued to the patient directly from Blueprint OMS, and once completed by the patient, stored in the patient record automatically.

Blueprints’ latest release features custom Online Forms, allowing electronic completion of intake paperwork, medical history, and surveys before a patient's appointment or for completion on a tablet in the waiting room. Information provided by the patient automatically creates a new patient record or updates the existing patient record in Blueprint OMS to eliminate all paper and manual data entry.

“The Ida Institute survey tools, together with practice's intake paperwork, are sent to the patient electronically as part of the appointment scheduling process. This allows patients to provide valuable information about their hearing situation and motivation level to the hearing health care provider prior to their visit for optimum appointment outcome. It is a major time-saving feature for both the patient and provider,” said Henrik Nielsen, the president of Blueprint Solutions.

DECIBEL THERAPEUTICS ANNOUNCES $82M FINANCING

Decibel Therapeutics announced the closing of an oversubscribed Series D financing, which raised $82.2M. The financing was led by OrbiMed, with new investments from BlackRock Health Sciences, Casdin Capital, Janus Henderson, Samsara BioCapital, and Surveyor Capital (a Citadel company). Existing investors also participated in the financing, including Foresite Capital, GV, S-Cubed Capital, Sobrato Capital, SR One, Third Rock Ventures, and other institutional investors. In conjunction with the financing, the company has appointed Peter A. Thompson, MD, FACP, a partner at OrbiMed, to its board of directors.

Proceeds will be used in part to support clinical and preclinical studies needed to advance Decibel's therapeutic pipeline. DB-OTO, Decibel's investigational gene therapy to restore hearing in children with congenital deafness due to a deficiency in the otoferlin gene, is in preclinical studies, and Decibel expects to initiate clinical testing in 2022. The program, developed in collaboration with Regeneron Pharmaceuticals, uses a proprietary, cell-selective promoter to precisely control gene expression in cochlear hair cells. DB-020, Decibel's investigational drug candidate to prevent the ototoxicity associated with cisplatin-based chemotherapy, is in a phase 1B study in cancer patients, with initial human efficacy data expected in 2021.

“Hearing and balance disorders have historically been overlooked by the biopharma industry, even though they exact a devastating toll on the lives of hundreds of millions of people around the globe. At Decibel, we are dedicated to restoring hearing and balance with precision therapeutics designed to deliver the right genetic medicine specifically to the right cells in the ear,” said Laurence Reid, PhD, the chief executive officer of Decibel. “We are grateful to this group of outstanding investors for choosing to partner with us to advance this vision.”

SIGNIA STYLETTO X NOW AVAILABLE THROUGH THE VA

Signia's Styletto X is now available for audiologists within the U.S. Department of Veterans Affairs (VA), the Department of Defense, and the Indian Health Service.

Research shows that veterans are 30 percent more likely than non-veterans to have severe hearing loss (CDC, 2020). Despite the prevalence of hearing loss and tinnitus, not all veterans with these conditions choose to seek treatment.

“Styletto X from Signia was developed to fight the stigma of hearing aids, providing veterans with an option unlike any other solutions available through the VA. With its unique design on the outside, as well as advanced functionality inside, Styletto X can help more veterans decide to get the hearing help they need,” said John Murray, Signia's vice-president of government services.

Built upon the Signia Xperience technology platform, Styletto X hearing aids also feature acoustic-motion sensors, Bluetooth® connectivity, and wireless Qi charging, which can help veterans with dexterity issues.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.